Transatlantic Exchanges in Immuno-Oncology

Friday, May 13, 2022 | 08:30 EST/ 14:30 CEST


Cancer immunotherapy has brought major improvements to patient survival and quality of life when compared with previous standards of care, whether it be surgery, radiotherapy or chemotherapy. It is now a pillar of cancer care, having moved earlier in patient management from the metastatic setting to as early as the neoadjuvant setting in numerous cancer types. The understanding of how immune cells recognise and kill cancer cells, and how we can enhance their ability to fight cancer, is now essential for anyone working to develop new cancer treatments or apply them in clinic.

During this unique online conference, the esteemed experts from Dana-Farber Cancer Institute/Gustave Roussy/Paris-Saclay University will review their latest clinical research and data covering a broad spectrum of immuno-oncology. We are pleased to announce that the keynote will be given by Professor William Kaelin, the 2019 Nobel Prize in Physiology or Medicine recipient.

Join our transatlantic panel of experts for an interactive, full-day virtual conference to be up to date with all the most exciting discoveries in immuno-oncology!




8:30 EST / 14:30 CEST

Chairmen Introduction

Fabrice Barlesi, MD, PhD/Toni Choueiri, MD

8:45 EST / 14:45 CEST

Keynote: The VHL Tumor Suppressor Gene as a Rosetta Stone for Kidney Cancer

William G Kaelin, Jr., MD

9:25 EST / 15:25 CEST

cGAS-Like Receptors Reveal New Signals Controlling Innate Immunity

Philip Kranzusch, PhD

9:55 EST / 15:55 CEST

Epigenetic Control of T Cell Memory and CAR T cell Persistence

Sebastian Amigorena, PhD


11:00 EST / 17:00 CEST

Immunogenic Cell Stress and Death

Guido Kroemer, MD, PhD

11:30 EST / 17:30 CEST

Tumour Macrophage Heterogeneity

Florent Ginhoux, PhD

12:00 EST / 18:00 CEST LUNCH BREAK

13:00 EST / 19:00 CEST

Microbiota-Centered Interventions for the Future of Immuno-Oncology

Laurence Zitvogel, MD, PhD

13:30 EST / 19:30 CEST

Engineered NK Cells for Enhanced Cancer Immunotherapy

Rizwan Romee, MD

14:00 EST / 20:00 CEST

GPRC5D- and Dual-Targeted CAR T Cell Therapy

Eric Smith, MD, PhD

14:30 EST / 20:30 CEST

Translation Control in Melanoma

Caroline Robert, MD, PhD


15:30 EST / 21:30 CEST

On the Path to Better Cancer Vaccines

Catherine J. Wu, MD

16:00 EST / 22:00 CEST

Immune Contexture and Immunoscore in the Era of Cancer Immunotherapy

Jérôme Galon, PhD

16:30 EST / 22:30 CEST

The Biology Behind PD-1 Checkpoint Blockade

Arlene Sharpe, MD, PhD

17:00 EST / 23:00 CEST

Conference Conclusion

Guido Kroemer, MD, PhD / Kai Wucherpfennig, MD, PhD